Interleukin 2 (il-2) and CD123 NK cell engager combination therapy
TW202626093APending Publication Date: 2026-07-01SANOFI SA(FR)
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- TW114133904
- Authority / Receiving Office
- TW · TW
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-09-04
- Filing Date
- 2025-09-04
- Publication Date
- 2026-07-01
Abstract
The present disclosure relates to methods of treating cancer with the combination of a binding protein comprising a first and a second antigen binding domain (ABD), wherein the first ABD binds specifically to human CD123 and the second ABD binds specifically to human NKp46, and an interleukin 2 (IL-2) polypeptide.
Need to check novelty before this filing date? Find Prior Art